RCUS — Arcus Biosciences, Inc.
$18.54-4.24%
Last close: · regular session
Pre-market $18.25 -1.56% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RCUS in the TickerWise workspace.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NYSE
- Employees: 627
- Website: https://www.arcusbio.com
Latest SEC filings for RCUS
Latest RCUS news
- Arcus Biosciences prices $250M public offering at $17.50 per share Read article
- Arcus Biosciences slides 20% on stock offering, kidney-cancer data Read article
- Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug Read article
- Arcus Biosciences Announces New Employment Inducement Grants Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.